Skip Navigation LinksHome > December 2010 - Volume 20 - Issue 9 > Prognostic and Predictive Values of E-Cadherin for Patients...
International Journal of Gynecological Cancer:
doi: 10.1111/IGC.0b013e3181e68a4d
Ovarian Cancer

Prognostic and Predictive Values of E-Cadherin for Patients of Ovarian Clear Cell Adenocarcinoma

Ho, Chih-Ming MD, PhD*†‡; Cheng, Wen-Fang MD, PhD§; Lin, Ming-Chieh MD∥; Chen, Tze-Chien MD¶; Huang, Shih-Hung MD#; Liu, Fu-Shing MD**; Chien, Chan-Chao Chang MD††; Yu, Mu-Hsien MD, PhD‡‡; Wang, Tao-Yeuan MD§§; Hsieh, Chang-Yao MD, MSPH§

Collapse Box

Abstract

Objectives: The purpose of the study was to analyze negative versus positive immunoexpression of epithelial cadherin (E-cadherin) and p53 in patients with primary advanced ovarian clear cell adenocarcinoma (OCCA) and its significance in relation to clinical features, progression-free survival and overall survival (OS).

Methods and Materials: Protein expression of E-cadherin and p53 was immunohistochemically evaluated in 61 OCCA patients with stages IIC to IV. The clinical factors studied included stage, age, CA-125, residual tumors, and chemotherapy regimens.

Results: Positive p53 immunoexpression was 44.8% (26/58) of OCCAs; in contrast, E-cadherin immunoexpression was observed in 75.9% (44/58) of OCCAs. The expected 5-year OS rate of OCCA treated with paclitaxel-based chemotherapy was significantly better than non-paclitaxel-based chemotherapy (40% vs 0%, P = 0.001). The expected 5-year OS rate of OCCA patients with positive E-cadherin immunoexpression (>10%) was also significantly better than patients with negative E-cadherin immunoexpression (≤10%) (35% vs 0%, P = 0.02). The expected 5-year OS rate of those receiving paclitaxel-platinum chemotherapy was not significantly different from platinum-based chemotherapy for those with negative E-cadherin immunoexpression (P = 0.11). The expected 5-year OS rate of those receiving paclitaxel-based chemotherapy was better than non-paclitaxel-based chemotherapy for those with positive E-cadherin immunoexpression (43% vs 0%, P = 0.01). Paclitaxel-based chemotherapy and positive E-cadherin immunoexpression were 2 independent prognostic factors in OS of patients with OCCA (P = 0.01 and 0.04, respectively).

Conclusions: E-cadherin is a useful prognostic marker for OCCA patients, and paclitaxel-based chemotherapy can improve survival among patients with positive E-cadherin immunoreactivity.

Copyright © 2010 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.